-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Qin Shengying team of the Bio-X Research Institute of Shanghai Jiao Tong University published a research paper on Multi-omics analysis identifies rare variation in leptin/PPAR gene sets and hypermethylation of ABCG1 contribute to antipsychotics-induced metabolic syndromes
Antipsychotic drug treatment is the main clinical treatment of schizophrenia and many other psychiatric diseases, but about 40% of patients will have the adverse reaction of drug-induced metabolic syndrome after receiving antipsychotic treatment, which seriously affects the quality of life of patients with schizophrenia and leads to a decrease in medication compliance, bringing a huge medical burden
This paper focuses on the subpopulation of patients with metabolic syndrome after treatment with schizophrenia antipsychotic drugs, and uses high-throughput multi-omics techniques such as whole genome association analysis, whole exome sequencing analysis, whole genome methylation analysis and transcriptome sequencing to find that a number of common and rare genetic variants are related to the occurrence of drug-induced metabolic syndrome
Dr.
Thesis link:
Bio-X Research Institute
Bio-X Research Institute